cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Arcutis Biotherapeutics Inc
2 own
1 watching
Current Price
$0
$0
(0%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
525.22M
52-Week High
52-Week High
27.4
52-Week Low
52-Week Low
7.25
Average Volume
Average Volume
0.76M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization525.22M
icon52-Week High27.4
icon52-Week Low7.25
iconAverage Volume0.76M
iconDividend Yield--
iconP/E Ratio--
What does the Arcutis Biotherapeutics Inc do?
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
Read More
How much money does Arcutis Biotherapeutics Inc make?
News & Events about Arcutis Biotherapeutics Inc.
Zolmax
2 months ago
Arcutis Biotherapeutics (NASDAQ:ARQT Get Rating) had its target price cut by equities researchers at Truist Financial from $50.00 to $45.00 in a note issued to investors on Wednesday, The Fly reports. The brokerage presently has a buy rating on the stock. Truist Financials target price points to a ...
Globe Newswire
2 months ago
New INTEGUMENT-1 and INTEGUMENT-2 data show a rapid and significant reduction in itch as early as 24 hours after the first application of roflumilast cream 0.15%Rapid and significant improvements were achieved including individuals reaching a 75% reduction of Eczema Area and Severity Index (EASI-75...
Globe Newswire
2 months ago
Late breaking session to highlight new data from the INTEGUMENT Phase 3 trials evaluating roflumilast cream in atopic dermatitisNew national survey insights depicting disease burden, path to diagnosis and treatment patterns for seborrheic dermatitisNew clinical safety and efficacy data of topical ...
Zolmax
3 months ago
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT Get Rating) Research analysts at Cantor Fitzgerald dropped their FY2023 earnings per share estimates for shares of Arcutis Biotherapeutics in a report issued on Wednesday, March 1st. Cantor Fitzgerald analyst L. Chen now forecasts that the company will earn...
Globe Newswire
3 months ago
Seborrheic dermatitis is an inflammatory skin disease affecting more than 10 million individuals in the United StatesIf approved, roflumilast foam would be the first topical drug for seborrheic dermatitis with a new mechanism of action in over two decadesIn a pivotal Phase 3 trial, 80% of ...
Frequently Asked Questions
Frequently Asked Questions
What is Arcutis Biotherapeutics Inc share price today?
plus_minus_icon
Can Indians buy Arcutis Biotherapeutics Inc shares?
plus_minus_icon
How can I buy Arcutis Biotherapeutics Inc shares from India?
plus_minus_icon
Can Fractional shares of Arcutis Biotherapeutics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Arcutis Biotherapeutics Inc stocks?
plus_minus_icon
What is today’s traded volume of Arcutis Biotherapeutics Inc?
plus_minus_icon
What is today’s market capitalisation of Arcutis Biotherapeutics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Arcutis Biotherapeutics Inc?
plus_minus_icon
What percentage is Arcutis Biotherapeutics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Arcutis Biotherapeutics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$0
$0
(0%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00